アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hcl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin hcl is indicated for the treatment of: - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms' tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma - metastatic transitional cell bladder carcinoma - metastatic thyroid carcinoma - metastatic gastric carcinoma - metastatic bronchogenic carcinoma doxorubicin hcl is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] - severe h

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - doxorubicin hydrochloride 10 mg/5 ml - concentrate for solution for infusion - 2 mg/ml - doxorubicin hydrochloride 50 mg/ml - doxorubicin

カナダ - 英語 - Health Canada

omega laboratories limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

イスラエル - 英語 - Ministry of Health

abic marketing ltd, israel - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - to produce regression in disseminated neoplastic conditions such as: - acute lymphoblastic leukemia, - acute myeloblastic leukemia, - wilms' tumor neuroblastoma, - soft tissue and bone sarcomas, - breast carcinoma, - lymphomas of both hodgkin's and non-hodgkin's types, - bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types, - gastric carcinoma.

マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - antineoplastic agents

マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - doxorubicin hydrochloride - solution for infusion - doxorubicin hydrochloride 2 mg/ml - antineoplastic agents

カナダ - 英語 - Health Canada

novopharm limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

カナダ - 英語 - Health Canada

strides pharma canada inc - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin